FSD Pharma Adds Biotech/LifeSciences Industry veteran James A. Datin and Robert J. Ciaruffoli, Former Chairman & CEO of Parente Beard/Baker Tilly to Board of Directors

C.HUGE, FSD Pharma, cannabis, pot

FSD Pharma Inc. (CSE: HUGE) (OTCQB: FSDDF) (FRA: 0K9) (“FSD” or the “Company”), today announced the appointment of James A. Datin and Robert J. Ciaruffoli, CPA to the Company’s Board of Directors. read more

FSD Pharma Adds Two More Prominent Cannabis Researchers to Scientific Advisory Board

Ziva Cooper, Ph.D. and Mallory Loflin, Ph.D. become latest members of the renowned group of FSD Scientific Advisors led by Charles Pollack, Jr. MD, FACEP
C.HUGE, FSD Pharma, cannabis, pot

FSD Pharma Inc. (CSE: HUGE) (OTCQB: FSDDF) (FRA: 0K9) (“FSD” or the “Company”), is pleased to announce the addition of two distinguished cannabis researchers to the company’s Scientific Advisory Board (“SAB”). read more

Dr. Raza Bokhari, FSD Pharma Executive Co-Chairman and CEO to Participate in Biotech-Focused Panel at the 2019 BIO International Convention

Panel to Feature Discussion About Creating a Winning Culture in the Biotech Industry
C.HUGE, FSD Pharma, cannabis, pot

FSD Pharma Inc. (CSE: HUGE) (OTCQB: FSDDF) (FRA: 0K9) (“FSD” or the “Company”), announced today that Executive Co-Chairman and Chief Executive Officer, Dr. Raza Bokhari, will be featured in the 2019 BIO International Convention’s panel presentation, “Building a Winning Team for Biotech Business Success – Lessons You Can Learn from Industry Veterans and Former NFL Player Turned Broadcaster Solomon Wilcots,” on June 4 in Philadelphia, PA. read more

FSD Pharma Welcomes All-Star Lineup of Cannabis Researchers to Scientific Advisory Board

Daniele Piomelli, Ph.D., Ryan Vandrey, Ph.D. and David Casarett, MD, MA Join distinguished group of Scientific Advisors
C.HUGE, FSD Pharma, cannabis, pot

FSD Pharma Inc. (CSE: HUGE) (OTCQB: FSDDF) (FRA: 0K9) (“FSD” or the “Company”), is pleased to announce that three eminent cannabis researchers have joined the company’s Scientific Advisory Board (“SAB”). read more

Keeping Up with FSD Pharma

Canada gold, junior mining companies

As well as yesterday’s announcement of a collaboration with Solarvest BioEnergy Inc to research using its algal expression technology to develop pharmaceutical-grade cannabinoids, FSD Pharma (CSE.HUGE) is also involved with Aura Health Inc. (CSE:BUZZ). This collaboration will give FSD Pharma a window into the medical marijuana market in Germany and, eventually, the EU generally. read more

World Class Congratulates Quadron on Scaling Up Hemp and Cannabis Extraction Capacity by Up to 800,000 lbs Per System Per Year

World Class Extractions Inc. (CSE: PUMP) (“World Class” or the “Company”) would like to congratulate Quadron Cannatech Corporation (“Quadron”) on its introduction of the Big BOSS, the latest model of Quadron’s automated, next generation hemp and cannabis extraction system. According to Quadron’s press release dated May 1, 2019, the Big BOSS provides the same advantages as the distinguished BOSS, but with significantly larger processing capabilities. The Big Boss is capable of processing up to 3,000 lb biomass per day, which translates to 66,000 lbs biomass processing per month (based on operating the Big BOSS 5 days per week), and nearly 800,000 lbs biomass processing per year. read more

FSD Pharma to Acquire Prismic Pharmaceuticals

This transaction positions FSD to help contribute to addressing the opioid crisis through use of synthetic cannabinoids
C.HUGE, FSD Pharma, cannabis, pot

FSD Pharma Inc. (CSE: HUGE) (OTCQB: FSDDF) (FRA: 0K9) (“FSD Pharma” or the “Company”) and Prismic Pharmaceuticals Inc. (“Prismic”), a US-based specialty R&D pharmaceutical company, announced today that they have entered into a securities exchange agreement dated April 22, 2019 (the “Agreement”) pursuant to which FSD Pharma has agreed to acquire all of the outstanding securities of Prismic (the “Transaction”). Prismic is developing novel non-addictive prescription drugs with unique safety profiles with the goal of addressing the opioid crisis based on formulations utilizing micro-palmitoylethanolamide’s (“PEA”) “entourage” effect on certain drugs impacting the endocannabinoid system. read more

FSD Pharma Receives Cannabis Sales License from Health Canada

New license positions FSD to serve the growing medicinal use markets
C.HUGE, FSD Pharma, cannabis, pot

FSD Pharma Inc. (CSE: HUGE) (OTCQB: FSDDF) (FRA: 0K9) (“FSD” or the “Company”), announced today that its wholly-owned subsidiary FV Pharma Inc. has received its Sale for Medical Purposes license to sell cannabis under the Cannabis Act (Canada). The license went into effect on April 18, 2019. read more

FSD Pharma to Present at Arcview Investor Forum

– Participate in panel presentations on a variety of issues affecting the industry
C.HUGE, FSD Pharma, cannabis, pot

FSD Pharma Inc. (CSE: HUGE) (OTCQB: FSDDF) (FRA: 0K9) (“FSD” or the “Company”), announced today that Dr. Raza Bokhari, Co-Chairman and Chief Executive Officer of FSD Pharma will participate in the Arcview Investor Forum being held April 23-25, 2019, in Vancouver. The event will feature leading public and private companies and thought leaders who are shaping the future of the industry. read more

FSD Pharma Appoints Charles Pollack Jr. MD, FACEP as Chairman of the

C.HUGE, FSD Pharma, cannabis, pot

FSD Pharma Inc. (CSE: HUGE) (OTCQB: FSDDF) (FRA: 0K9) (“FSD” or the “Company”), announced today the appointment of Charles V. Pollack, Jr., M.A., M.D., FACEP, FAAEM, FAHA, FACC, FESC, FCPP, as Chairman of its Scientific Advisory Board (“SAB”). In this capacity Dr. Pollack will serve as a strategic guide and resource to the Company as it develops disruptive, science-based, cannabinoid therapeutics. read more